Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Synaptogenix Inc (SNPX)

Synaptogenix Inc (SNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...

SNPX : 5.09 (+6.93%)
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis PR Newswire - Wed Jul 19, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 5.09 (+6.93%)
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire - Tue Mar 7, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 5.09 (+6.93%)
Wall Street - shutterstock_1321462400
Pre-Market Brief: Stocks Mixed As Recession, Rate Hike Fears Persist Barchart - Mon Dec 19, 2022

March S&P 500 futures (ESH23) are trending up +0.39% this morning after three major U.S. benchmark indices slid for a third successive session and suffered a second consecutive week of losses on Friday...

ESH23 : 3,957.05s (-0.09%)
ARDX : 8.72 (+28.42%)
TSLA : 181.19 (+0.66%)
CTLT : 56.50 (+0.28%)
HEXO : 0.7100 (+2.45%)
SNPX : 5.09 (+6.93%)
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease PR Newswire - Fri Dec 16, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 5.09 (+6.93%)
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results PR Newswire - Wed Sep 28, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 5.09 (+6.93%)
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network PR Newswire - Fri Aug 12, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 5.09 (+6.93%)
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data PR Newswire - Tue Jul 26, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 5.09 (+6.93%)
Synaptogenix Announces Corporate Update Conference Call PR Newswire - Thu Jul 21, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 5.09 (+6.93%)
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data PR Newswire - Wed Jul 20, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 5.09 (+6.93%)

Barchart Exclusives

3 High-Yield Dividend Stocks Ready to Soar Barchart - Fri May 3, 6:00PM CDT
These three stocks are cheap, pay a high dividend, and are highly rated. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot